Search research articles
Contact Us
Filters
Showing results (81-90 of 217) with videos related to
Page
of 22
Sort By:
Bulletin Du Cancer
|
August 12, 2023
Alejandra Martínez, Cyrus Chargari, Elsa Kalbacher, et al.
Molecular Cancer Therapeutics
|
April 1, 2025
Pharmacological inhibition of SIRT1 limits the growth of tumoral and metastatic granulosa cells by impacting mTOR, Myc and E2F pathways
Victoria Cluzet, Eloïse Airaud, Arnaud Tete, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 14, 2021
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)
Susana Banerjee, James Stewart, Nuria Porta, et al.
Gynecologic Oncology
|
November 9, 2020
Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape
Félix Blanc-Durand, Catherine Genestie, Elisa Yaniz Galende, et al.
Bulletin Du Cancer
|
September 6, 2013
[Uterine leiomyosarcoma: epidemiology, pathology, biology, diagnosis, prognosis and treatment]
Julien Hadoux, Philippe Morice, Catherine Lhommé, et al.
International Journal of Molecular Sciences
|
July 29, 2023
Combined Tumor-Based <i>BRCA1/2</i> and <i>TP53</i> Mutation Testing in Ovarian Cancer
Edith Borcoman, Elizabeth Santana Dos Santos, Catherine Genestie, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 22, 2020
Predicting tumor response and outcome of second-look surgery with <sup>18</sup>F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer
Nicolas Aide, Pauline Fauchille, Elodie Coquan, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 7, 2025
Prognostic Value of a Joint K-PD Model With Tumor Size Dynamics and CA-125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study
Aurore Carrot, Pauline Corbaux, Olivier Colomban, et al.
Gynecologic Oncology
|
February 20, 2026
Para-aortic lymphadenectomy after negative PET-CT in locally advanced cervical cancer: a continuous monocentric series of 320 cases
Mathilde Daix-Moreux, Houssein El Hajj, Stéphanie Schérier, et al.
Nature Communications
|
March 5, 2024
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Gilles Freyer, Anne Floquet, Olivier Tredan, et al.
Page
of 22
Search research articles
Search
Showing results (81-90 of 217) with videos related to
Sort By:
Page
of 22
Bulletin Du Cancer
|
August 12, 2023
Alejandra Martínez, Cyrus Chargari, Elsa Kalbacher, et al.
Molecular Cancer Therapeutics
|
April 1, 2025
Pharmacological inhibition of SIRT1 limits the growth of tumoral and metastatic granulosa cells by impacting mTOR, Myc and E2F pathways
Victoria Cluzet, Eloïse Airaud, Arnaud Tete, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 14, 2021
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)
Susana Banerjee, James Stewart, Nuria Porta, et al.
Gynecologic Oncology
|
November 9, 2020
Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape
Félix Blanc-Durand, Catherine Genestie, Elisa Yaniz Galende, et al.
Bulletin Du Cancer
|
September 6, 2013
[Uterine leiomyosarcoma: epidemiology, pathology, biology, diagnosis, prognosis and treatment]
Julien Hadoux, Philippe Morice, Catherine Lhommé, et al.
International Journal of Molecular Sciences
|
July 29, 2023
Combined Tumor-Based <i>BRCA1/2</i> and <i>TP53</i> Mutation Testing in Ovarian Cancer
Edith Borcoman, Elizabeth Santana Dos Santos, Catherine Genestie, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 22, 2020
Predicting tumor response and outcome of second-look surgery with <sup>18</sup>F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer
Nicolas Aide, Pauline Fauchille, Elodie Coquan, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 7, 2025
Prognostic Value of a Joint K-PD Model With Tumor Size Dynamics and CA-125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study
Aurore Carrot, Pauline Corbaux, Olivier Colomban, et al.
Gynecologic Oncology
|
February 20, 2026
Para-aortic lymphadenectomy after negative PET-CT in locally advanced cervical cancer: a continuous monocentric series of 320 cases
Mathilde Daix-Moreux, Houssein El Hajj, Stéphanie Schérier, et al.
Nature Communications
|
March 5, 2024
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Gilles Freyer, Anne Floquet, Olivier Tredan, et al.
Page
of 22